Pancreas-on-a-Chip Technology for Transplantation Applications
- PDF / 599,596 Bytes
- 13 Pages / 595.276 x 790.866 pts Page_size
- 29 Downloads / 164 Views
IMMUNOLOGY, TRANSPLANTATION, AND REGENERATIVE MEDICINE (L PIEMONTI AND V SORDI, SECTION EDITORS)
Pancreas-on-a-Chip Technology for Transplantation Applications Shadab Abadpour 1,2 & Aleksandra Aizenshtadt 2 & Petter Angell Olsen 2 & Kayoko Shoji 2 & Steven Ray Wilson 2,3 & Stefan Krauss 2,4 & Hanne Scholz 1,2 Accepted: 26 October 2020 # The Author(s) 2020
Abstract Purpose of Review Human pancreas-on-a-chip (PoC) technology is quickly advancing as a platform for complex in vitro modeling of islet physiology. This review summarizes the current progress and evaluates the possibility of using this technology for clinical islet transplantation. Recent Findings PoC microfluidic platforms have mainly shown proof of principle for long-term culturing of islets to study islet function in a standardized format. Advancement in microfluidic design by using imaging-compatible biomaterials and biosensor technology might provide a novel future tool for predicting islet transplantation outcome. Progress in combining islets with other tissue types gives a possibility to study diabetic interventions in a minimal equivalent in vitro environment. Summary Although the field of PoC is still in its infancy, considerable progress in the development of functional systems has brought the technology on the verge of a general applicable tool that may be used to study islet quality and to replace animal testing in the development of diabetes interventions. Keywords Islet transplantation . Pancreas transplantation . Stem cell-derived beta-like cells . Type 1 diabetes . Organ-on-a-chip . Microfluidic systems . Pancreas-on-a-chip . Multi-organ-on-a-chip
Introduction Type 1 diabetes (T1D), which is mainly referred to as the insulin-dependent disease, results from an immune-mediated destruction of beta cells within the pancreatic islets [1]. Exogenous insulin therapy has shown to be effective to
maintain the glucose homeostasis and reduce the complications associated with T1D, but it poorly mimics the normal beta cell function and comes with the risk of hypoglycemic episodes [2]. Beta cell replacement therapy in the form of both pancreas transplantation and allogeneic islet transplantation has proven to be a safe alternative treatment to external insulin
This article is part of the Topical Collection on Immunology, Transplantation, and Regenerative Medicine * Hanne Scholz [email protected] Shadab Abadpour [email protected]
Stefan Krauss [email protected]
1
Department of Transplant Medicine and Institute for Surgical Research, Oslo University Hospital, Post Box 4950, Nydalen, N-0424 Oslo, Norway
2
Hybrid Technology Hub-Centre of Excellence, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway
3
Department of Chemistry, University of Oslo, Oslo, Norway
4
Institute of Immunology, Oslo University Hospital, Oslo, Norway
Aleksandra Aizenshtadt [email protected] Petter Angell Olsen [email protected] Kayoko Shoji [email protected] Steven Ray Wilson s.r.h.wi
Data Loading...
